Dr. Daniel Gray, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 157
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Perelman School of Med at the University of Pennsylvania
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
NY license 200474
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Strong Memorial Hospital Rochester, NY
- Highland Hospital Rochester, NY
- F F Thompson Hospital Canandaigua, NY
- Geneva General Hospital Geneva, NY
Medical groups
- Strong Renal Group (48 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 157
- Services billed
- 443
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Hemodialysis procedure with physician evaluation | 92 | 44 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 80 | 20 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 74 | 37 |
| Established patient office or other outpatient visit, 40-54 minutes | 63 | 52 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 36 | 22 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 21 | 20 |
| Established patient office or other outpatient visit, 30-39 minutes | 18 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 21 payments worth $162 in total to this clinician.
| Travere Therapeutics, Inc. | $162 |
|---|
| Food and Beverage | $125 |
|---|---|
| Education | $36.95 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Feb 6, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
| Travere Therapeutics, Inc. Mar 28, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
| Travere Therapeutics, Inc. May 8, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
| Travere Therapeutics, Inc. Jun 11, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
| Travere Therapeutics, Inc. Jun 26, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
| Travere Therapeutics, Inc. Jul 28, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
| Travere Therapeutics, Inc. Aug 4, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
| Travere Therapeutics, Inc. Apr 30, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. May 8, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. May 13, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
All 20 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Oct 13, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Oct 8, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Sep 8, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Aug 21, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Aug 7, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Aug 4, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
| Travere Therapeutics, Inc. Aug 4, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Jul 28, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
| Travere Therapeutics, Inc. Jul 7, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Jun 26, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
| Travere Therapeutics, Inc. Jun 26, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Jun 11, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
| Travere Therapeutics, Inc. Jun 11, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. May 13, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. May 8, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
| Travere Therapeutics, Inc. May 8, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Apr 30, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Mar 28, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
| Travere Therapeutics, Inc. Mar 11, 2025 | Education Filspari · Kidney Disease · in-kind | $0.37 |
| Travere Therapeutics, Inc. Feb 6, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $450 in research payments for these studies, mostly to the institutions running them.
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.